DXCM 53.03 Dexcom Inc $DXCM Hit a 52 week high of 54.00

New Post Public Reply Private Reply Replies (0) Message Board

Nov 11, 2014 at 11:39 AM

DXCM 53.03 Dexcom Inc $DXCM Hit a 52 week high of 54.00 Currently at 53.03 -0.47 -0.88% With a day low of 52.75 and a total volume of 62,031.

DXCM Dexcom Inc Recent Headline News

DexCom G4 Platinum Software Gains FDA Nod, Shares Surge - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 1:54PM CST
Following the announcement, shares of DexCom, Inc. (DXCM) shot up nearly 14.12% to close at $50.93 in the last trading session.
ABT: 44.59 (+0.50), JNJ: 109.33 (+0.51), DXCM: 53.14 (-0.36), MDT: 69.26 (+0.55)

DexCom Has Returned 17.2% Since SmarTrend Recommendation (DXCM)
Comtex SmarTrend(R) - Mon Nov 10, 9:32AM CST
SmarTrend identified an Uptrend for DexCom (NASDAQ

XCM) on October 21st, 2014 at $43.32. In approximately 3 weeks, DexCom has returned 17.21% as of today's recent price of $50.77.
DXCM: 53.14 (-0.36)

Strength Seen in DexCom (DXCM): Stocks Gains 14.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 8:46AM CST
DexCom (DXCM) was a big mover last session, with shares rising over 14% on the day.
ABMD: 32.99 (unch), DXCM: 53.14 (-0.36), EW: 125.20 (+0.60), ANGO: 16.98 (+0.02)

Hologic Beats Q4 Earnings, Sales as All Segments Gain - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 1:50PM CST
Hologic (HOLX) entered into an amended license agreement with Roka Bioscience, which earned a one-time revenue benefit of $20.1 million for Hologic
ABMD: 32.99 (unch), DXCM: 53.14 (-0.36), ANGO: 16.98 (+0.02), HOLX: 26.72 (+0.17)

Watch Out: Barbarians At The Gate For DexCom (DXCM)
at The Street - Fri Nov 07, 8:55AM CST
Trade-Ideas LLC identified DexCom (DXCM) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
DXCM: 53.14 (-0.36)

Foundation Medicine Slumps: FMI Tumbles 9.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:59AM CST
Foundation Medicine has been witnessing a flat trend in its current year earnings estimate and its share price has been falling for past 24 hours
ABMD: 32.99 (unch), DXCM: 53.14 (-0.36), FMI: 24.90 (+0.19), ANGO: 16.98 (+0.02)

DexCom's (DXCM) CEO Terry Gregg on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 9:13PM CST

DXCM: 53.14 (-0.36)

DexCom misses by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:09PM CST

DXCM: 53.14 (-0.36)

DexCom (DXCM) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 06, 3:25PM CST

DXCM: 53.14 (-0.36)

DexCom, Inc. Reports Third Quarter 2014 Financial Results
Business Wire - Thu Nov 06, 3:02PM CST
DexCom, Inc. (Nasdaq: DXCM) today reported its unaudited financial results as of and for the quarter ended September 30, 2014.
DXCM: 53.14 (-0.36)

FDA Approves Dexcom Software with Artificial Pancreas Algorithm
Business Wire - Thu Nov 06, 7:30AM CST
Dexcom, Inc., (NASDAQ

XCM), a leader in continuous glucose monitoring (CGM), announced today that the U.S. Food and Drug Administration (FDA) has approved new software for the Dexcom G4(R) PLATINUM CGM. The new Software 505 features the same advanced algorithm as used in artificial pancreas research around the world. The software will impact the performance of the Dexcom G4 PLATINUM, already considered the most accurate CGM system on the market today. The software will be made available free of charge to adult patients using the Dexcom G4 PLATINUM.
DXCM: 53.14 (-0.36)

Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:35PM CST

BEBE: 2.39 (+0.01), ACET: 21.29 (-0.12), ANET: 76.39 (-0.40), FNGN: 31.54 (+0.19), CPST: 0.96 (+0.01), AUQ: 3.56 (+0.35), AMRN: 0.79 (-0.04), ED: 63.56 (+0.09), ENV: 52.69 (+0.57), FXCM: 16.60 (+0.02), BCEI: 40.46 (+0.27), GXP: 27.17 (+0.02), EAC: 12.63 (-0.32), DXCM: 53.14 (-0.36), CSC: 59.76 (+0.45), AEL: 27.38 (-0.46), HNSN: 0.70 (-0.05), CFN: 57.51 (-0.01), ANAC: 31.49 (+0.95), DAR: 18.88 (+0.11), GST: 4.00 (-0.02), ARC: 10.08 (-0.09), FIVN: 4.74 (-0.09), ELON: 1.97 (-0.06), FSLR: 51.42 (-0.54), EZPW: 10.87 (-0.12), ALIM: 5.19 (+0.05), FWM: 2.33 (-0.10), BRS: 71.85 (+0.78), ECOM: 18.44 (+0.10), FTEK: 4.01 (-0.04), CVT: 28.27 (-0.24), AL: 37.52 (-0.22), BBRG: 13.01 (+0.39), BPZ: 0.92 (-0.04), ECPG: 45.36 (+0.13), HTGC: 16.15 (+0.05), AIRM: 43.43 (-0.05), BNFT: 25.28 (-0.22), ENOC: 14.98 (-0.07), HPTX: 21.74 (+0.16), AGO: 24.58 (unch), FICO: 71.31 (+0.58), FF: 12.79 (-0.26), FI: 19.11 (+0.03), EVC: 5.16 (+0.02), EBS: 24.22 (+0.27), ABCO: 46.99 (-0.47), DIOD: 25.98 (-0.06), DIS: 89.58 (-0.20), EGOV: 17.13 (+0.12), APEI: 35.80 (-0.25), DVA: 74.90 (+0.18), CLVS: 61.00 (+0.86), HCI: 44.37 (+0.46), BRKR: 18.18 (+0.24), HGR: 21.04 (+0.45)

DexCom Announces Upcoming Conference Presentations
Business Wire - Thu Oct 30, 7:30AM CDT
DexCom, Inc. (NASDAQ

XCM) today announced that management will present an update on DexCom at the following upcoming investor conferences:
DXCM: 53.14 (-0.36)

Forget MannKind Corporation: 3 Better Stocks
Motley Fool Staff - Motley Fool - Mon Oct 27, 8:13AM CDT
Source: MannKind. A doubling of Americans diagnosed with diabetes over the coming decade may support demand for MannKind 's inhalable insulin Afrezza, but that doesn't necessarily mean that MannKind is biotech's best idea. We asked three of...
DXCM: 53.14 (-0.36), NVAX: 5.34 (+0.13), AGIO: 84.64 (+2.86), SNY: 46.83 (+0.64), MNKD: 6.00 (+0.12), CELG: 108.48 (+0.47)

DexCom reports November 6
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 9:43AM CDT

DXCM: 53.14 (-0.36)

DexCom Schedules Third Quarter 2014 Earnings Release and Conference Call for November 6, 2014 at 4:30 p.m. Eastern Time
Business Wire - Thu Oct 23, 7:31AM CDT
DexCom, Inc. (NASDAQ

XCM) today announced that it plans to release its third quarter 2014 financial results after market close on Thursday, November 6, 2014. Management will hold a conference call to review the company's third quarter 2014 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. website at www.dexcom.com by navigating to "Our Company," then "Investor Relations," and then "Events and Webcasts," and will be archived there for future reference.
DXCM: 53.14 (-0.36)

FDA Approves Dexcom SHARE(TM), the First Remote Mobile Communications Device Used for Continuous Glucose Monitoring (CGM)
Business Wire - Mon Oct 20, 8:24AM CDT
Dexcom, Inc. (NASDAQ

XCM), a leader in continuous glucose monitoring (CGM) for patients with diabetes, announced today that it has received U.S. Food and Drug Administration (FDA) approval for its CGM remote mobile communications device: Dexcom SHARE. Dexcom SHARE, an accessory to the Dexcom G4(R) PLATINUM Continuous Glucose Monitoring System, uses a secure wireless connection to transmit the glucose levels of a person with diabetes to the smartphones of up to five designated recipients, or "followers." These followers can remotely monitor a patient's glucose information and receive alert notifications from almost anywhere via their Apple(R) iPhone(R) or iPod(R) touch. With Dexcom SHARE, parents and personal caregivers can monitor a child's or loved one's glucose data from a remote location, giving them peace of mind and reassurance when they are apart.
DXCM: 53.14 (-0.36)

MFG, PGTI, MWIV, BKD, AREX, DXCM Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Mon Oct 06, 6:29AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Mizuho Financial Group Inc (NYSE:MFG), PGT Inc (NASDAQ

GTI), MWI Veterinary Supply Inc (NASDAQ:MWIV), BROOKDALE SENIOR LIVING INC. (NYSE:BKD), Approach Resources Inc (NASDAQ:AREX), DexCom Inc (NASDAQ

XCM) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
MFG: 3.55 (-0.06), DXCM: 53.14 (-0.36), MWIV: 154.38 (-0.45), PGTI: 9.73 (+0.02), BKD: 32.95 (-0.13), AREX: 10.72 (+0.11)

The Stunning Mobile Game Changer for Diabetics That Investors Can't Ignore
Leo Sun, The Motley Fool - Motley Fool - Sun Oct 05, 8:31AM CDT
Ever since Apple launched the first iPhone nearly seven years ago, developers have released mobile apps and connected devices to improve the lives of diabetes patients. These products helped diabetics track meals, insulin dosages, glucose...
JNJ: 109.34 (+0.52), DXCM: 53.14 (-0.36), MDT: 69.26 (+0.55), SNY: 46.83 (+0.64), AAPL: 108.87 (+0.04)

Technical Report on Health Care Equipment Stocks - Baxter Intl., Covidien, Becton Dickinson, Thoratec, and DexCom
PR Newswire - Wed Sep 17, 8:05AM CDT
On Tuesday, September 16, 2014, the NASDAQ Composite ended at 4,552.76, up 0.75%, the Dow Jones Industrial Average advanced 0.59%, to finish the day at 17,131.97, and the S&P 500 closed at 1,998.98, up 0.75%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 744.20, up 1.34%, with the index also advancing 7.96% in the previous three months. Investor-Edge has initiated coverage on the following equities: Baxter International Inc. (NYSE: BAX), Covidien PLC (NYSE: COV), Becton Dickinson and Company (NYSE: BDX), Thoratec Corporation (NASDAQ: THOR), and DexCom Inc. (NASDAQ: DXCM). Free research on these five companies can be accessed at:
BDX: 128.81 (+0.51), DXCM: 53.14 (-0.36), BAX: 70.82 (+0.19), COV: 93.75 (+0.11), THOR: 27.50 (+0.20)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Alaska's Insurance Maze: Coverage Over Cheap Policies

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

ASTS Faces Crucial Deadline Amidst Legal Turmoil

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Spooky Dining at CARNE: A Halloween Hit in Oxnard

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Bio-Thera's New Data: A Game Changer for NSCLC?

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Gildan Faces Lawsuit: Allegations of Deceptive Practices Shake Investors

Gildan's Troubles Unveiled The financial jungle can be a pretty treacherous place, and Gildan Activewear Inc. (NYSE: GIL) just found out how fickle the market can be. An 18.7% nosedive in Gildan's stock price after a securities fraud class action came knocking—if that isn't enough to stir up a hornet’s nest among investors, I don’t know what is. The Catalyst:...

TORRAS Stands Tall with iPhone 18 Pro Cases

By Riley Hayes Updated Oct 24, 2026 Category News Views 191

TORRAS Shines in Magnetic Stand Case Evaluation In the whirlwind of smartphone accessories, where the battle lines are drawn between protection and functionality, TORRAS has emerged victorious with its magnetic stand cases for the iPhone 18 Pro and its beefier brother, the iPhone 18 Pro Max. Expert Consumers—a trusted name in product evaluations—has given TORRAS the...

Axon Body 5: A Leap Forward in AI for Public Safety

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Aluminum Design Fumble: Geometry Over Wall Thickness

A Misstep in Aluminum Design Practices Well, here's a nugget of wisdom for the metal enthusiasts out there—stop beefing up aluminum components with thicker walls and focus on smart geometry. This isn't a drill, folks. Mark Coyle, a seasoned mind over at American Custom Metals, has been waving the flag for smarter aluminum design methods right from Rochester, NY, and...

Lilly's Sofe-M Shakes Up Ovarian Cancer Treatment

Ovarian Cancer Treatment Sees a New Challenger Alright, folks, Eli Lilly (NYSE:LLY) is stepping up with their latest findings in ovarian cancer treatment, and it's got plenty of people in a buzz. They've dropped new data for their investigational drug, Sofetabart mipitecan, or 'Sofe-M' for short, which targets this unrelenting disease with a punch that’s hard to ignore....

Master Sommeliers and Italian Producers Clash on Wine Lists

Wines Jockeying for New York’s Coveted Lists Alright, picture a stage set up in New York City like an arena. But instead of gladiators, you've got master sommeliers on one side and Italian wine producers on the other, each armed with their own arguments. They're locked in a battle over what it really takes to get a bottle imbedded on a New York City's prestigious wine...